Haverford Trust Co. elevated its position in shares of Eli Lilly and Co by 16.3%

Haverford Trust Co. lifted its position in shares of Eli Lilly and Co by 16.3% during the fourth quarter, according to the company in its most recent filing with the SEC.

The institutional investor owned 6,105 shares of the company’s stock after buying an additional 854 shares during the quarter. Haverford Trust Co.’s holdings in Eli Lilly and were worth $516,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in LLY. Beach Investment Management LLC. bought a new stake in Eli Lilly and in the 2nd quarter valued at $400,000.

Martingale Asset Management L P increased its holdings in Eli Lilly and by 143.3% in the 2nd quarter. Martingale Asset Management L P now owns 333,046 shares of the company’s stock valued at $27,411,000 after acquiring an additional 196,167 shares during the last quarter. Financial Counselors Inc. increased its holdings in Eli Lilly and by 0.4% in the 2nd quarter.

Financial Counselors Inc. now owns 92,508 shares of the company’s stock valued at $7,613,000 after acquiring an additional 350 shares during the last quarter. Vantage Financial Partners Ltd. Inc. bought a new stake in Eli Lilly and in the 2nd quarter valued at $494,000. Finally, Omnia Family Wealth LLC increased its holdings in Eli Lilly and by 3.6% in the 2nd quarter.

Omnia Family Wealth LLC now owns 3,263 shares of the company’s stock valued at $269,000 after acquiring an additional 113 shares during the last quarter. Institutional investors own 75.71% of the company’s stocks.

LLY has been the topic of a number of research reports. JPMorgan Chase & Co. set a $105.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Monday, February 26th. Jefferies Group set a $93.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a report on Monday, February 26th. Bank of America reduced their target price on shares of Eli Lilly and from $88.00 to $86.00 and set a “neutral” rating on the stock in a report on Thursday, February 1st.

Credit Suisse Group restated a “hold” rating and issued a $80.00 target price on shares of Eli Lilly and in a report on Friday, February 2nd. Finally, BMO Capital Markets boosted their target price on shares of Eli Lilly and from $73.00 to $74.00 and gave the stock an “underperform” rating in a report on Thursday, February 1st.

Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. Eli Lilly and has an average rating of “Hold” and a consensus target price of $93.47.